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Summary P-glycoprotein (PGP) is an energy-dependent efflux pump that serves to protect cells against the
cytotoxicity of many natural product drugs including vinblastine (VBL). In this study we investigated the role
of PGP in regulating initial VBL influx. The apparent influx of VBL, measured over the first 20 s, was 2-fold
lower in KB-GRCI cells expressing a transfected mdrl gene at high level than in non-expressing parental
KB-3-1 cells. Inhibition of PGP efflux function with dipyridamole increased the influx rate constant by 4.0-fold
in the KB-GRC1 cells but only 2.1-fold in the KB-3-1 cells. Verapamil, another inhibitor of PGP-mediated
efflux, increased the initial influx rate constant by 2.7-fold in the KB-GRCI cells but only 1.4-fold in the
KB-3-1 cells. Inhibition of PGP function by depletion of ATP increased influx by 6.8-fold and 2.2-fold in the
two cell types, respectively. Mutation of PGP at both ATP binding sites abolished its ability to limit initial
influx. Thus, VBL is serving as an efficient substrate for the efflux pump even within the first few seconds of
drug exposure, consistent with the hypothesis that PGP may directly efflux drug from the cell membrane.
Overexpression of the mdrl gene coding for the production
of a 170 kd glycoprotein, PGP3, is often a prominent feature
of the MDR phenotype (Endicott & Ling, 1989; Juranka et
al., 1989). Transfection of the mdrl gene into drug-sensitive
clones confers drug resistance to cells that overexpress PGP
(Debenham et al., 1986; Shen et al., 1986; Euda et al., 1987).
The transmembrane location, energy dependence, correlation
with resistance and extensive homology of the mdrl product
with bacterial transport proteins is consistent with PGP act-
ing as an energy-dependent efflux pump (Juranka et al., 1989;
Beck, 1987; Gros et al., 1986; Chen et al., 1986). A major
strategy in reversing the MDR phenotype is to utilise agents
that inhibit PGP function (Ford & Hait, 1990; Tsuruo et al.,
1981). For example, VPL's ability to inhibit drug efflux in
many tumour types has been attributed to'its ability to bind
to PGP (Cornwell et al., 1987; Safa, 1988; Naito & Tsuruo,
1989), but the modulation is absent in MDR cell lines that
do not overexpress the mdrl gene as their primary mechan-
ism of resistance (Cole et al., 1989).
There are a few reports indicating that mdrl overexpres-
sion may be associated with a change in drug influx (Ramu
et al., 1989), or may fail to alter efflux (Deffie et al., 1988),
and modulators of the MDR phenotype such as VPL do not
inhibit drug efflux in every MDR cell line overexpressing
mdrl (Fojo et al., 1985). These data are difficult to interpret
in light of the commonly accepted role of PGP as an efflux
transporter. PGP shares extensive sequence homology with
two major classes of transporters: (1) the multicomponent
periplasmic protein-binding permeases that import substrates
and (2) the hemolysin B-like proteins that export substrates
(Juranka & Ling, 1989; Gross et al., 1986; Chen et al., 1987;
Ames Ferro-Luzzi, 1986). The homology with proteins that
transport substrates in and out of cells suggests that PGP is
related to both types of transporters, and raises the question
of whether PGP might have an influx function in addition to
its efflux role (Riordan & Ling, 1985).
We have observed that overexpression of PGP decreases
the initial influx of VBL over the first 20 s employing drug-
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sensitive KB-3-1 and MDR KB-GRCl cells*. KB-GRC1
cells theoretically differ from KB-3-1 cells only by expression
of PGP following transfection of mdrl (Choi et al., 1988),
and are 67, 9.4, 4.5 and 1.5-fold cross-resistant to VBL,
doxorubicin, colchicine and etoposide, respectively (ibid.,
Shalinsky et al., 1990a). Inhibition of PGP efflux function
with two pharmacologic agents, DPM and VPL, increased
initial influx. Reduction in efflux pump activity by depletion
of ATP or mutation at the ATP binding sites also increased
initial VBL influx. We conclude that PGP functions to
decrease the apparent initial influx of VBL, and this decrease
is mediated by the ability of PGP to efflux drug. Thus, VBL
is serving as an efficient substrate for the efflux pump even
within the first few seconds of drug exposure, consistent with
the hypothesis that PGP directly effluxes drug from the cell
membrane.
Materials and methods
Drugs and chemicals
DPM was a gift from Boehringer Ingelheim Pharmaceuticals,
Inc. (Ridgefield, CT). DPM was dissolved in absolute ethanol
to produce a stock concentration of 9.9 mM. G-418 sulfate
was purchased from GIBCO (Grand Island, NY). VBL sul-
fate was obtained from Eli Lilly & Co. (Indianapolis, IN).
VPL hydrochloride was purchased from American Regent
Laboratories, Inc. (Shirley, NY). NAN3 and the Biolumines-
cent Somatic Cell Assay Kit (FL-ASC) were purchased from
Sigma Chemical Co. (St. Louis, MO). Stock solutions of
these drugs were made by dissolving them in saline. Working
solutions were prepared by further dilution in tissue culture
medium. Propidium iodide was obtained from Calbiochem
Co. (La Jolla, CA). TPP+ (97% pure) was purchased from
Aldrich Chemical Co. (Milwaukee, WI). [3H]-TPP+ (23 Ci
mmol-1) was purchased from Amersham Radiopharmaceuti-
cals Inc. (Arlington Heights, IL) and stored at -20°C in
ethanol.
[3H]-VBL (10-20Cimmol'1) in methanol was purchased
under a special quality-control contract to ensure high purity
from Moravek Biochemicals (Brea, CA), stored in the dark
at - 80°C and protected from light during experiments. The
purity of [3H]-VBL as a single peak was confirmed by HPLC
*Portions of this work have been published in abstract form (Shalin-
sky et al., 1990a; Shalinsky & Howell, 1991).
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analysis according to the method of Thimmaiah and Sethi
(1985). [3H]-VBL was stable for at least 2 months when
stored at -80°C. In addition, HPLC analysis of [3H]-VBL
extracted from cellular homogenates indicated no decomposi-
tion under the experimental conditions employed in these
studies. The final specific activity of the [3H]-VBL used for
drug accumulation studies was 6.67 mCi j.mol-'.
Cell lines and culture medium
The drug sensitive KB-3-1 line (Akiyama et al., 1985) and its
multidrug resistant subline, KB-GRCI, were obtained from
Dr. Igor Roninson (University of Illinois, College of Medi-
cine, Chicago, IL). The KB-GRCl line was derived by trans-
fection of the wild-type mdrl gene coupled to a Moloney
Murine Leukemia Virus long terminal repeat into KB-3-1
cells (Choi et al., 1988). Routine culture of these cells has
been previously described (Shalinsky et al., 1990b).
Mouse L cell variants, KK, MM and NEO (Morse &
Roninson, 1990), were also obtained from Dr Roninson. KK
cells were produced by transfection of the human wild-type
mdrl gene into parental fibroblast mouse L cells. MM cells
were produced by transfection of a non-functional form of
the mdrl gene containing mutations at the ATP binding sites
into parental fibroblast mouse L cells; specifically, lysine was
mutated to methionine at positions 433 and 1076 in the
amino acid sequence. NEO cells were produced by transfec-
tion of the vector without the mdrl insert into parental
fibroblast cells and represented the transfectant control cell
line. Overexpression of functional and non-functional PGP in
KK and MM cells was confirmed by staining of the respec-
tive cell ine with the monoclonal P-glycoCHEK C219 anti-
body (Centocor, Inc., Malvern, PA), and by measuring drug
uptake and sensitivity. L cell variants were grown in the
presence of 0.4 mgml-' G-418 sulfate. All cells were grown
at 37°C under 5% CO2 in air in T25 or T75 tissue culture
flasks (Corning Glass Works, NY).
Modulation ofcellular pharmacology
Six nM [3H]-VBL and modulator (20fM) were rapidly added
to subconfluent monolayer cultures in 60-mm dishes in 2 ml
of culture medium equilibrated overnight in the CO2 incu-
bator at 37°C as described (ibid.). At appropriate time points,
the medium was aspirated and the cells were washed
(3 x 5 ml) with ice cold PBS (Oxoid, Columbia, MD). Incu-
bations were carried out in the CO2 incubator at 37°C for all
time points ) 1 min. For time points A 1 min, incubations
were carried out using medium pre-equilibrated in the CO2
incubator at 37°C. Time points were recorded from the addi-
tion of [3H]-VBL alone or with modulator to the first aspira-
tion. The average time recorded from addition of 2 ml of
radiolabelled medium to the dish until aspiration was
0.89 ± 0.25 s, and uptake experiments under the first min
were highly reproducible with linear rate constants being
obtained (ri>0.93). The cells were then digested overnight
with 1 N NaOH, and neutralised aliquots were used for
determination of protein content and cell associated radio-
activity.
The percent of intracellular [3H]-VBL that was in a bound
form during uptake was determined by exposing monolayer
cells to [3H]-VBL for I h, washing the cells in PBS, resus-
pending in 1 ml of PBS and scraping with rubber policeman
for transfer into 15 ml tubes. The cellular suspension was
sonicated three times for 10 s on ice to destroy cellular
membranes using a Vibra-cell (VC-50) sonicator (Sonics &
Materials, Inc., Danbury, CT) set to 25 watts-/60 amplitude-
vibrations. An aliquot was removed, digested in 1 N NaOH,
neutralised with equimolar HCI, and counted by liquid scin-
tillation spectroscopy to determine total radioactivity. The
rest of the sonicated suspension was filtered through Centri-
feeR micropartition filters (Amicon, Beverly, MA) and the
ultrafilterable [3H]-VBL was counted by liquid scintillation
spectroscopy. The percent of bound drug was calculated by
subtracting the free ultrafiltrable amount of [3H]-VBL from
the total.
Efflux was determined after incubation of cells with 6 nM
[3H]-VBL for 2 h until steady-state had been reached. The
medium was aspirated, cells were washed with ice cold PBS,
and 2 ml of fresh VBL-free 37°C normal medium was added
back to the dishes. DPM or VPL was supplemented to this
medium to study the effect of these modulators on effux. At
designated time points, the fresh medium was aspirated and
the cells washed with ice cold PBS. The actual time between
addition of fresh medium and final aspiration was recorded
in each case. Efflux was monitored from 30 s to 3 h.
Measurement ofcellular ATP levels
Monolayers KB-GCRI and KB-3-1 cells were pretreated for
2 h with varying concentrations of NaN3 to deplete cellular
ATP levels. After washing with ice-cold PBS, the cells were
scraped from the dish and transferred to a plastic test tube as
a suspension of 1-10 x 106 cellsml1'. ATP levels were
measured using fire fly luciferase with the Bioluminescent
Somatic Cell Assay Kit [Sigma Chemical Co., St. Louis, MO;
(Leach, 1986)]. Light emission was monitored using a Mono-
light bioluminescent luminometer (Model 2001, Analytical
Luminescence Laboratory, San Diego, CA). A standard ATP
curve was run with each experiment to ensure that the con-
centration of ATP and resulting emission of light was in the
linear range. Data were expressed as light units relative to
control for each experiment.
Regression analysis ofinitial efflux and influx
In this study, initial efflux was defined as efflux over the first
120 s of incubation in VBL-free medium. Initial influx was
defined as the uptake over the first 20 s. The apparent uni-
directional influx and initial efflux rate constants in KB-
GRC1 and KB-3-1 cells were linear up to 240 s (r2>,0.93).
The rate constant for initial efflux was determined by
fitting a line to the efflux data over the first 120 s. Several
experiments, or runs, were performed under the same com-
bination of cell line and condition (control, VPL or DPM);
the equation for the i-th run was Ci(t) = Ai[l-ket], where Ci(t)
is the concentration of VBL at any time t, Ai is the initial
concentration of VBL at Cs. prior to efflux, as shown by the
fitted y-intercept, and ke is the rate constant for initial efflux.
Simultaneous fitting of the data from all runs was done to
obtain a single estimate of Ke; its standard error and degrees
of freedom appeared in the regression output. The statistic r2
for these fittings ranged from 0.983 to 0.998 across the
various combinations of cell line and condition. Similarly, for
each combination of cell line and condition, the rate constant
for influx was determined by fitting a line to the influx data
over the first 20 s ofinflux. The equation for the i-th run was
Ci(t) = AJ[l + ki,t], where Ci(t) is the time zero binding of
VBL, as shown by the fitted y-intercept, and kin is the rate
constant for initial uptake, i.e. influx. The statistic r2 for
these fittings ranged from 0.930 to 0.978 across the various
combinations of cell line and condition. The fitted rate con-
stants for efflux and influx were compared across the control,
VPL and DPM groups using the Satterwaite modification of
Student's t test.
Statistical analysis
Unless othersise noted, the data were expressed as the group
mean ± SE of duplicate determinations from each of n
experiments. The Student's t test for grouped data were used
unless otherwise stated. In all cases, significance was at the
level of P<0.05.
Results
Effect ofPGP on VBL influx
The KB-GRCI and KB-3-1 cell lines were employed because
they permitted a direct comparison of the effect of PGP on32 D.R. SHALINSKY et al.
VBL uptake without the confounding effects of other resis-
tance mechanisms associated with cells selected with increas-
ing concentrations of drug (Chabner & Fojo, 1989). Figure
la shows the time course of [3H]-VBL uptake in the parental
KB-3-1 and PGP-expressing KB-GRC1 cells. KB-GRC1 cells
accumulated VBL at a lower rate and to a smaller extent
than the parental KB-3-1 cells, consistent with the presence
of the PGP efflux transporter in KB-GRC1 cells. Expression
of PGP only in the KB-GRC1 cells was confirmed by stain-
ing of the cells with the C219 monoclonal antibody followed
by flow cytometric analysis (data not shown). The C,, or
VBL under control conditions was reached by 20 and 60 min
in KB-GRC1 and KB-3-1 cells, respectively. The Cs. was
5.2-fold lower in the KB-GRC1 than KB-3-1 cells. Figure lb
also shows the time course of efflux of [3H]-VBL. The KB-
GRC1 cells had a more rapid and extensive loss of [3H]-VBL.
The efflux data over the first 120 s were well fit by a first
order decay curve from which the initial efflux rate constant
was calculated (r2>0.983). As shown in Table I, the rate
constant for initial efflux was 2.5-fold higher in KB-GRC1
than KB-3-1 cells, confirming the presence of the PGP efflux
transporter in the KB-GRCl cells. After 10 min, KB-GRC1
cells had effluxed 53% of the drug they contained at steady-
state but KB-3-1 cells had effluxed only 24% of their steady-
state content. After 3 h, only 10% of the steady-state level of
VBL remained in KB-GRC1 cells compared to 50% in the
KB-3-1 cells. These results establish that the KB-GRC1 cells
have the transport characteristics expected as a result of high
level expression of a PGP efflux pump.
However, in addition to changes in Cs. and efflux, there
was a large difference in the initial influx of [3H]-VBL
between the KB-GRC1 and KB-3-1 cells measured over the
first few seconds of drug exposure (Figure 2). The initial
influx data were well fit by a straight line (r2>0.930) from
which the influx rate constant was calculated. As shown in
Table II, the rate constant for influx was 4.2-fold lower in
KB-GRC1 relative to KB-3-1 cells. A statistically significant
difference in uptake existed even at 5 s after the start of the
exposure (P<0.05). Figure 2 also shows that the influx was
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Table I Rate constants for initial efflux ofVBL over the first 120 s of
efflux
P value P value
Rate±s.e.a compared compared
Cell line Condition (min-') to Control to VPL
KB-GRC1 Controlb 0.130±0.011
VPL (20 gM) 0.112±0.012 0.308
DPM (20 sM) 0.074±0.013 0.009 0.052
KB-3-1 Control 0.052±0.014
VPL (20ElM) 0.047±0.004 0.765
DPM (20gM) 0.030±0.005 0.193 0.026
aData areexpressed as fitted estimate ofthe rate constant. Values are
mean±s.e from three experiments. bKB-GRC1 vs KB-3-1 control:
P-value = 0.002.
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Figure 2 Influx of [3H]-VBL in KB-GRC1 (0 O) and KB-
3-1 (0 ) cells under control conditions at 37°C. Influx was
also monitored at 4°C in the same cells (KB-GRCI, 0 0;
KB-3-1, 0. ). Each point is plotted as the mean±s.e. of 3-7
experiments.
Table II Rate constants for influx of VBL over the first 20 s ofdrug
exposure
P value P value
Rate±s.e.a compared compared
Cell line Condition (x 10- s-') to Control to VPL
KB-GRC1 Controlb 0.393±0.017
VPL (20 1M) 1.042±0.137 0.001
DPM (20 sM) 1.576±0.297 0.002 0.119
KB-3-1 Control 1.634±0.053
VPL (20JiM) 2.245±0.228 0.069
DPM (20gM) 3.413±0.372 0.013 0.013
aData are expressed as fitted estimate ofthe rate constant. Value are
mean±s.e. from 5-7 experiments. bKB-GRC1 vs KB-3-1 control:
P-value<0.001.
completely abolished when the cells were incubated at 4°C on
ice, indicating that diffusion of VBL into cells was stopped at
low temperature. Initial influx was not saturable in either cell
line at concentrations up to 324JIM (data not shown). These
data that show that expression of PGP results in a lower
initial influx rate, suggesting that PGP was able to rapidly
efflux VBL during the initial moments of exposure.
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Figure 1 Uptake a, and efflux b, of [3H]-VBL in KB-GRC1
(0 O) and KB-3-1 (0 0) cells under control conditions.
Cells were loaded with [3H]-VBL for 2 h prior to efflux. Each
point is plotted as the mean±s.e. of 3-4 experiments.
Effect ofDPM on VBL influx
If the effect of PGP on initial influx was dependent on its
efflux pump activity, then inhibition of the pump with phar-
macologic agents such as DPM should increase initial influx.
As shown in Figure 3, DPM produced an instantaneous
doubling of the time zero binding of [3H]-VBL in each cell
line. Pretreatment for up to 1 h did not alter the magnitude
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Figure 3 Influx of[3H]-VBL in KB-GRCl a, and KB-3-1 b, cells
in the presence of 20jM DPM or VPL. Influx is shown under
control conditions (0 0), with DPM (U U) and VPL
(O ). Each point is plotted as the mean±s.e. of 5-7
experiments.
of this effect (data not shown). The ability of DPM to
increase initial influx was determined by regression analysis
of the data over the first 20 s of incubation. These data were
well fit to a straight line (r2>0.930). Table II shows that
DPM increased the rate constant for influx by 4.0 and 2.1-
fold in KB-GRCl and KB-3-1 cells, respectively (P < 0.013).
DPM enhanced the influx in a dose-dependent saturable
manner to an equivalent level in both KB-GRCI and KB-3-1
cell lines (data not shown). The concentration of DPM
required to produce a half-maximal increase in influx was
3tLM in KB-GRCl cells and it was 1j.M in KB-3-1 cells.
Saturation of influx occurred at concentrations >20 SAM.
Concentrations of DPM <200jLM did not alter cellular
ability to exclude trypan blue under these conditions.
Measurement of the extent of bound intracellular VBL dem-
onstrated that 55% of the radiolabel was ultrafiltrable after a
1 h incubation. Twenty jaM DPM did not change the level of
ultrafilterable [3H]-VBL in two experiments, indicating that
the DPM-induced increase in 1 h accumulation was not due
to a change in a tightly-bound fraction of VBL to proteins of
,<25,000 molecular weight. Thus, this inhibitor of PGP did
in fact increase initial influx.
That DPM inhibited efflux pump activity was shown by its
effect on the time course of VBL efflux. Figure 4 shows that
DPM inhibited the efflux [3H]-VBL in both the KB-GRCl
and KB-3-1 cells with the most prominent effects observed in
KB-GRCI cells. DPM produced a statistically significant
decrease in both the initial efflux rate constant (Table I) and
the terminal rate constant from 0.00606 ± 0.00057 min-'
(SE) to 0.00005 ± 0.00037 (SE) min-' (P<0.00001) in KB-
GRC1 cells. This is reflected by the fact that DPM almost
completely blocked the efflux of [3H]-VBL after 30 min. Fur-
ther experiments indicated that the [3H]-VBL remaining in
the cell after 1 h of efflux in DPM-containing medium was
readily effluxable if DPM was removed from the efflux
medium (data not shown), confirming that DPM did not
lock VBL into an irreversibly-bound intracellular compart-
ment. In KB-3-1 cells, DPM did not significantly reduce the
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Figure 4 Efflux of [3H]-VBL in KB-GRC1 a, and KB-3-1 b,
cells. Cells were preloaded with radiolabelled VBL for 2 h prior
to efflux under control conditions (0- O), or in the presence
of 20jM DPM (0 0) or VPL (A A). Points are plotted
as the mean±s.e. of three experiments.
initial efflux or terminal rate constants (P.0.193), but still
had a significant effect on decreasing efflux by 1.9-fold
(P = 0.026) as shown in Figure 4.
Consistent with its ability to both increase influx and
inhibit efflux, DPM produced a large increase in the C.8 in
KB-GRCI cells that plateaued at a level 9.2-fold above
control at steady-state (data not shown). In comparison,
DPM elevated the C,, by only 1.8-fold in KB-3-1 cells, but
the enhancement was statistically significant (P<0.05, paired
t test).
Further experiments were conducted to examine whether
the effects of DPM were due to permeabilisation of the
cellular membrane. DPM did not affect the uptake or efflux
of [3H]-VBL in protein-free liposomes (data not shown) pre-
pared as previously described (Kim et al., 1989). In flow
cytometric studies, DPM did not alter the forward light
scatter of KB-3-1 cells, but the membrane permeabilising
agent, digitonin (Lepers et al., 1990), produced a maximal
increase within 75 s of incubation (data not shown). Digi-
tonin, but not DPM, also produced a large increase in
permeability to propidium iodide as determined by measur-
ing cellular fluorescence of this agent (data not shown).
Furthermore, DPM did not alter the membrane potential in
KB-3-1 cells as determined by measuring the accumulation of
[3H]-TPP+ at 2 h (Lichtshtein et al., 1979). These experiments
provided evidence that DPM did not permeabilise cellular
membranes.
As shown in Figure 2, there was a high time zero binding
of [3H]-VBL in tumour cells that was modulatable by DPM.
Liposomes were used as a model to determine whether this
initial binding was unique to cell membranes. Liposomes
incubated at 37°C had an initial time zero association of
3404 ± 257 (s.d.) c.p.m.; this value was reduced to
2267 ± 505 (s.d.) c.p.m. for liposomes incubated on ice at
4°C, respectively (n = 2). The modest decrease observed in
time zero binding with reduction in temperature in both34 D.R. SHALINSKY et al.
liposomes and cells, and the fact that significant time zero
binding occurred in both liposomes and cells suggested that
the time zero binding represents non-specific association of
VBL with membrane lipids.
Effect of VPL on VBL influx
Table II shows that VPL produced a 2.7-fold increase in the
rate constant for initial influx in KB-GRCl cells but only a
statistically insignificant 1.4-fold increase in KB-3-1 cells. The
influx data over the first 20 s of incubation were well fit to a
straight line (r2>0.930). VPL produced a 4.6-fold increase in
the C. of [3H]-VBL in KB-GRCI cells but the 1.3-fold
increase in C,, in KB-3-1 cells was statistically insignificant
(data not shown). As shown in Table I, VPL did not signifi-
cantly inhibit initial efflux in either cell line, in agreement
with a previously published report (Fojo et al., 1985). Thus,
VPL had more pronounced effects on initial influx than on
initial efflux, but the greatest effect was in mdrl-overexpress-
ing KB-GRCI cells. Thus, this inhibitor of PGP activity
preferentially increased influx as compared to inhibiting
efflux.
Effect ofmutation ofPGP on VBL influx
Further experiments were performed to determine the effect
on VBL influx of inactivating PGP by mutating ATP binding
sites. L cells were transfected with wild-type or mutationally
inactivated mdrl, and an empty vector to produce the KK,
MM and NEO sublines, respectively. The KK, MM and
NEO cell ines had a C. of 0.57 ± 0.26 (s.d.), 2.49 ± 0.10
(s.d.) and 2.07 ± 0.49 (s.d.) pmol VBLmg-' protein, respec-
tively (n = 2-3), and respective IC5o values in the clonogenic
assay of 166 ± 23 (s.d.), 25 ± 5 and 22 ± 3 (s.d.) nM for VBL
(n = 3-5, data not shown). KK cells were also 5-fold resis-
tant to colchicine compared to MM and NEO cellst, consis-
tent with the presence of abundant functional PGP uniquely
in KK cells. Staining with the monoclonal antibody C219
showed a high level of staining for PGP in the KK and MM
cell lines and no detectable level in NEO cells (data not
shown). While NEO cells express a low level of endogenous
PGPt, they served as an appropriate control for the KK and
MM cells, in which the transfection conferred detectable
levels of PGP and in the case of KK, an observable MDR
phenotype. In this model, the initial influx of VBL was
reduced in the KK cells documented to possess the functional
form of PGP relative to the other cell lines (Figure 5). The
presence of a high level of non-functional PGP did not alter
the influx rate in MM cells relative to the transfectant control
NEO cell line.
apparent influx truly represented inhibition of rapid efflux,
and that one could not interpret the influx period to truly
represent zero-trans influx in the KB-GRC1 cells.
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Figure 5 Influx of [3H]-VBL in mouse L cell variants, KK
(0 0, MM (U U), and NEO (0 O). Points
mean±s.e. of three experiments.
Table III Depletion ofATP levels by NaN3 in KB-GRCI and KB-3-1
cells
Per cent ATP remaining after 2h exposure to NaN3
NaN3 concentration (mM)
Cell line 10 50 100
KB-GRCI 49.4± 25.Oa 21.1 ± 1.4 19.6±4.8
KB-3-1 59.9±16.1 20.6±2.1 13.1±7.0
aValue are expressed as mean±s.d. oftwo experiments performed in
duplicate as described in Materials and methods.
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Effect ofenergy depletion on VBL influx
Since PGP is an energy-dependent pump, ATP depletion
would be expected to increase influx selectively in KB-GRCI
cells if PGP was responsible for the differences in influx
observed between KB-GRCI and KB-3-1 cells. Therefore,
cellular ATP content was depleted. Table III shows that
NaN3 depleted cellular ATP levels in a dose-dependent man-
ner. Cellular viability was >94% after exposure to NaN3,
and this treatment did not affect efficiency when the cells
were subsequently seeded in normal medium (data not
shown). Figure 6 shows that pretreatment for 2 h with
100 mM NaN3 increased the influx of VBL by 6.8 and 2.2-
fold in KB-GRCI and KB-3-1 cells, respectively. The fact
that ATP depletion equalised the influx rate indicated that
the efflux pump activity ofPGP was responsible for the lower
rate even at times <20s. These data supported the hypo-
thesis that the efflux function ofPGP was fully active even at
the earliest time intervals and indicated that effects on the
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Figure 6 Initial influx of [3H]-VBL in KB-GRCI a, and KB-3-l
b, cells. Influx was monitored under normal energy-replete condi-
tions (0 0) and under energy-depleted conditions produced
by pre-incubation with 100 mM NaN3 ( 0 . Points are
mean±s.e. of three experiments.
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Discussion
Cells that overexpress the mdrl gene have decreased steady-
state accumulation and increased efflux of many anticancer
drugs including VBL (Endicott & Ling, 1989; Juranka et al.,
1989). The product of the mdrl gene, PGP, is thought to
function as an energy-dependent efflux pump, and drugs such
as VPL are believed to reverse the MDR phenotype by virtue
of their ability to bind to PGP and inhibit efflux activity
(reviewed in Ford & Hait, 1990). KB-GRCI and KB-3-1 cells
theoretically differ from each other only by virtue of the
presence of overexpressed amounts of PGP in the former
cells (Choi et al., 1988), and as anticipated, the KB-GRCl
cells accumulated less VBL at steady-state, and effluxed VBL
more rapidly. KB-GRC1 cells, however, also demonstrated a
much lower rate of initial VBL influx than KB-3-1 cells.
During the first few seconds of VBL influx, one would
expect that the cytosolic concentration of VBL would be at
its lowest level relative to the levels that would be achieved
over time, and thus that efflux would be relatively unimpor-
tant and incapable of influencing the rate of initial influx.
However, the presence of PGP in the membrane did decrease
initial influx measured over the first few seconds. Three
possible explanations present themselves. The first and
second possibilities are that the presence of PGP in the
membrane decreases diffusional permeability to VBL, or
decreases its intracellular trapping. Favouring this is the fact
that PGP is known to export acids (Gros et al., 1986; Chen
et al., 1987; Ames Ferro-Luzzi, 1986) and may serve as a
chloride channel (Valverde et al., 1992), and thus could
indirectly alter the intracellular environment to decrease drug
trapping. The third possibility is that PGP may be effluxing
VBL directly from the cell membrane or cytoplasm under
conditions which are not zero-trans.
Several lines of evidence favour the latter argument. First,
when the efflux function of PGP was inhibited by DPM, an
MDR modulator that binds to PGP to produce synergy with
VBL (Asoh et al., 1989; Shalinsky et al., 1990b; Shalinsky et
al., 1991b), initial influx increased, and did so to a greater
degree in the KB-GRC1 cells over-expressing PGP than in
the KB-3-1 cells that do not express detectable amounts by
Northern or polymerase chain reaction analyses of mdrl
mRNA (Akiyama et al., 1985; Chaudary & Roninson, 1991).
That DPM can function as an inhibitor of the efflux activity
of the PGP was shown by the fact that it produced a
statistically significant reduction in the initial efflux of VBL
from preloaded cells. The fact that DPM inhibited efflux and
did not alter membrane permeability indicates that its actions
were specifically and primarily targeted to inhibiting PGP
efflux activity. Like DPM, VPL also increased initial influx,
and did so to a greater extent in KB-GRCI than KB-3-1
cells. Although the effect of VPL on inhibiting initial efflux
did not reach the level of statistical significance, VPL has
been shown to be an effective inhibitor of the efflux function
of PGP in numerous other studies (Ford & Hait, 1990).
Second, when the efflux pump function of PGP was eliminat-
ed by ATP depletion, the initial influx rate increased, and the
effect was larger in the cells expressing the greater amount of
PGP. Third, while mouse L cells transfected with a func-
tional form ofthe mdrl gene demonstrate a decrease in initial
influx compared to control cells transfected with the same
vector not containing the mdrl gene, cells transfected with a
mutated mdrl producing a nonfunctional PGP do not have
impaired initial influx. Thus, the presence of large amounts
of PGP containing only a single amino acid substitution in
each of the ATP binding sites was not by itself able to alter
initial influx, arguing that simply the presence of the protein
in the membrane did not change diffusional permeability to
VBL.
While these kinetic studies could not distinguish between
efflux from the membranal or cytoplasmic compartments, we
believe that the data are most consistent with the hypothesis
that PGP can export substrates directly from the cellular
membrane. In support of this concept is the rapidity with
which efflux activity was observed and inhibited, and the fact
that most substrates and modulators of PGP activity are
lipophilic (Ford & Hait, 1990) and thus would be expected to
interact more highly within the lipid membrane bilayer. Fur-
thermore, reports in the literature indicate that PGP serves as
a hydrophobic membrane 'vacuum cleaner' to export drug
from the cellular membrane (Gros et al., 1986; Raviv et al.,
1990; Gottesman & Pastan, 1990). A more prominent role
for the membranal rather than cytoplasmically-bound sub-
strate is invoked by the work of Raviv et al. (1990) who have
reported that doxorubicin interacts with a site on PGP within
the cellular membrane. In addition, identification of putative
binding sites close to or within the transmembrane regions of
PGP would also support this hypothesis (Choi et al., 1988;
Greenberger et al., 1991; Gros et al., 1991; Hait & Aftab,
1992).
If PGP can utilise VBL in the membrane compartment as
a substrate, then what appears to be a reduction in initial
influx is in fact due to the ability of the pump to rapidly
efflux VBL. Other investigators have also demonstrated the
ability of PGP to efflux VBL and doxorubicin within millisec
to sec of exposure in MDR cells (Cano-Gauci et al., 1990),
and modulators of the MDR phenotype have been shown to
inhibit PGP-chloride-associated channel activity within 30 s
of exposure (Valverde et al., 1992) providing further support
for the concept than that PGP can efflux drug even after very
short periods of drug exposure, and that modulators can act
rapidly enough to account for their ability to increase initial
uptake within a few seconds of addition to the culture.
In summary, this report demonstrates that the KB-GRC1
cell line presents a good model for the study of PGP function
at short time intervals. Specifically, PGP-mediated efflux can
be quantitated at short time points as can the efflux-modulat-
ing activity of MDR chemosensitisers such as DPM and
VPL. These data are consistent with the hypothesis that PGP
directly effluxes drug from the cellular membrane.
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